INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE /// EXPLORE NOW INTRODUCING TEMPUS NEXT: AI-ENABLED CARE PATHWAY INTELLIGENCE ///

Tempus xR

Whole transcriptome RNA sequencing

xR is a whole transcriptome RNA-seq panel for solid tumors and hematologic malignancies that reports clinically relevant1 fusions for more than 100 targeted genes2, as well as altered splicing events for MET exon 14 and EGFRvIII

Contact us
  • Depth of sequencing

    50 million reads (avg.)

  • Alterations identified

    Rearrangements, fusions, altered splicing for MET Exon 14 and EGFRvIII

  • Tumor type

    Heme & solid

  • Sensitivity

    97% for rearrangements/ fusions, 100% for altered splicing (MET Exon 14),  95.5% for altered splicing (EGFRvIII)3

    View validation summary
  • Accepted sample types

    FFPE slides, blocks, frozen samples, extracted RNA, peripheral blood, bone marrow

  • Platforms used

    Illumina NovaSeq

OUR SCIENCE

Use of clinical RNA-sequencing in the detection of actionable fusions compared to
DNA-sequencing alone

In a pan-cancer analysis (n=2,118) of specific gene fusion events, RNA-seq consistently improved the detection of fusions compared to DNA-seq alone across all cancer types, with 1,106 fusions classified as targetable by OncoKB indication-matched therapies, 19% (214) of which were identifiable through RNA-seq alone, 5% (54) by DNA-seq alone, and 76% (838) identifiable through RNA- and DNA-seq.4

Learn more
image description

Comprehensive solutions for every stage of clinical development

See our full suite of NGS assays

LEARN MORE
the value of rna

Powering novel discoveries at every
stage of therapeutic development

In addition to fusion detection, RNA-seq offers several advantages to biopharma and researchers—from target discovery and selection through CDx development.

Learn more about the value of RNA-seq
  • Molecular Characterization: Characterizing the prevalence or degree of overexpression in late-stage tumors

  • Mechanistic Studies: Understanding the pharmacokinetics and pharmacodynamics of novel therapies

  • Predicting Drug Sensitization & Resistance: Identify predictive expression profiles to isolate mechanisms of drug response and resistance

  • Trial Recruitment: RNA-seq can screen patients for overexpression of genes to be used as a surrogate for IHC or screening tool to identify patients likely to be IHC+ for multiple tests

  • Clinical Design: By performing full genomic and transcriptomic characterization of patients entering a trial, one can identify molecular signatures of response or resistance to refine biomarker strategy in later phases

  • CDx Development: RNA-seq offers alternatives to traditional CDx biomarkers such as single gene overexpression, transcriptional signatures of pathway activation or immune activity

  • Indication Expansion: Retrospective analysis of RNA-seq data can identify label expansion opportunities by selectively identifying cancer types and post-treatment settings with high expression of genes that are targeted by a therapy

  • Real-World Market Analysis: Clinical RNA-seq of a broad population can be paired with treatment records and outcomes data, to quantify the uptake of IHC testing and prescription rates to identify areas for growth and monitor real-world efficacy

Tempus offers broad panels for both DNA- and RNA-based sequencing

Tempus xR can be ordered standalone or in combination with Tempus xT, providing a comprehensive view of genomic profiles.

Learn more about our NGS assays
  • Tempus xR Whole transcriptome RNA sequencing panel
  • Tempus xT 648 gene DNA sequencing panel, tumor/normal matched

IN DEVELOPMENT

Tempus xR IVD

The Tempus xR IVD assay is in development as a next generation sequencing in vitro diagnostic (IVD) test that uses targeted high throughput hybridization-based capture technology for detection of oncogenically relevant gene rearrangements, and altered splicing in two genes, using RNA isolated from formalin-fixed paraffin embedded (FFPE) tissue specimens from previously diagnosed cancer patients with solid malignant neoplasms.

Biomarkers for assay validation
ALTERATION TYPEBIOMARKERINDICATION
Biomarkers for assay validationGene Rearrangements (fusions as a class)Oncogenically Relevant GenesSolid Tumors
Altered SplicingMET exon 14 skippingLung Cancer, Gastrointestinal Malignancy
Altered SplicingEGFRvIIICNS Glioma
Additional biomarkers scoped for validation
Additional biomarkers scoped for validationGene RearrangementsBRAF (IUO)Solid Tumors
Altered SplicingBRAF (IUO)Solid Tumors
  1. Clinically relevant fusions are defined as alterations that are associated with available therapeutic options, prognostic implications, diagnostic relevance, or clinical trial enrollment opportunities for a specific variant identified in a patient’s tumor or hematologic malignancy.
  2. Examples of targeted genes include but are not limited to: ALK, RET, ROS1, NTRK1/2/3, FGFR1/2/3, NRG1, BRAF, EWSR1, PML-RARA, BCR-ABL.
  3. Performance specifications of the Tempus xR assay in Tempus’ Chicago, IL, laboratory. For Durham, NC lab performance specifications, see the xR validation summary.
  4. Michuda J, Park BH, Cummings AL, et al. Use of clinical RNA-sequencing in the detection of actionable fusions compared to DNA-sequencing alone. J Clin Oncol. 2022;40(16_suppl):3077.

This is data-driven precision medicine

This is the future of healthcare.